To explore this possibility, we investigated whether HBPDS has an ability to improve neurological impairment and reduce spinal demyelination and inflammation in the myelin oligodendrocyte glycoprotein peptide (MOG35-55)-induced experimental autoimmune encephalomyelitis (EAE) mice model, an animal model of MS. Here, MOG is linked to experimental autoimmune encephalomyelitis.